Drugs / PD-1 Knockout T Cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02867332 | Nov 2016 → Nov 2020 | renal cell carcinoma | Peking University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02863913 | Sep 2016 → Sep 2019 | urinary bladder carcinoma | Peking University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03525652 | Feb 2018 → Feb 2021 | prostate cancer | The First Affiliated Hospital of Guangdong Pharmaceutical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1 Knockout T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03525652 ↗ |
| Action | Inhibit | “Programmed cell death protein 1(PDCD1) gene will be knocked out” NCT02863913 ↗ |
| Modality | Cell therapy | “ex-vivo knocked-out, expanded, and selected PD-1 knockout-T cells from autologous origin” NCT02863913 ↗ |
| Target | PDCD1 | “Programmed cell death protein 1(PDCD1) gene will be knocked out” NCT02863913 ↗ |